The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s showing significant potential in clinical trials for managing obesity. Unlike some existing weight loss treatments, retatrutide appears to offer a significant substantial de